A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

ClinicalTrials.gov ID: NCT05063734

Public ClinicalTrials.gov record NCT05063734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-687 Injections and to Evaluate the Efficacy and Safety of THR-687 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).

Study identification

NCT ID: NCT05063734
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Oxurion; Industry
Enrollment: 16 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 26, 2021
Primary completion: Jun 28, 2022
Completion: Jun 28, 2022
Last update posted: Aug 17, 2023

2021 – 2022

United States locations

U.S. sites: 18
U.S. states: 10
U.S. cities: 18

Facility	City	State	ZIP	Site status
Salehi Retina Institute Inc.	Huntington Beach	California	92647	—
California Eye Specialists Medical Group, Inc.	Pasadena	California	91107	—
Retinal Consultants Medical Group	Sacramento	California	95825	—
Retina Consultants of Southern Colorado, P.C.	Colorado Springs	Colorado	80909	—
Retina Associates, Ltd	Elmhurst	Illinois	60126	—
University Retina and macula Associates, PC	Oak Forest	Illinois	60452	—
Cumberland Valley Retina Consultants	Hagerstown	Maryland	21740	—
Sierra Eye Associates	Reno	Nevada	89502	—
Retina Vitreous Surgeons of Central New York, PC	Liverpool	New York	13088	—
Tulsa Retina Consultants	Tulsa	Oklahoma	74114	—
Eye Care Specialists	Kingston	Pennsylvania	18704	—
Tennessee Retina, PC	Nashville	Tennessee	37203	—
Austin Research Center of Retina	Austin	Texas	78705	—
Retina Consultants of Texas	Katy	Texas	77494	—
Valley Retina Institute, P.A.	McAllen	Texas	78503	—
Medical Center Ophthalmology Associates	San Antonio	Texas	78240	—
Retina Center of Texas	Southlake	Texas	76092	—
Strategic Clinical Research Group	Willow Park	Texas	76087	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05063734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 17, 2023 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05063734 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →